Analytical Data
-
Gene name
DBL
- Application
-
Alternative Names
/
-
Species
Plasmodium falciparum
-
Source
Baculovirus
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
ACM48350.1
-
Expression Region
1-353aa
-
Molecular Weight
45.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DBL (Duffy Binding-Like) recombinant proteins are pivotal in the study of malaria, particularly due to their role in the interaction between the malaria parasite, Plasmodium falciparum, and the host's red blood cells. The binding of P. falciparum to Duffy antigen receptors on erythrocytes is a critical step in the invasion process, making DBL proteins integral to understanding malaria pathology and host-parasite interactions. Research on these proteins has gained momentum as scientists seek to elucidate the mechanisms of immune evasion and identify potential targets for vaccine development. Moreover, since certain populations lack the Duffy blood group antigen, this highlights the varying susceptibility to malaria across different ethnic groups, prompting further investigation into the genetic basis of malaria resistance. By utilizing recombinant DNA technology, researchers can produce DBL proteins in the laboratory, allowing for detailed studies of their structure, function, and immunogenicity. This has significant implications not only for vaccine research but also for understanding the broader context of malaria transmission dynamics and developing effective control strategies. As global efforts to combat malaria intensify, studying DBL proteins offers a promising avenue for novel therapeutic interventions and enhancing our understanding of malaria resilience and resistance mechanisms.
